# US 2021/0260159 A1 · CD40L-Fc FUSION POLYPEPTIDES AND METHODS OF USE THEREOF

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0260159 A1
- Document ID: US20210260159A1
- Status: Published application
- Kind: A1
- Application number: 17/194,658
- Filed: 2021-03-08
- Published: 2021-08-26
- Earliest claimed: 2016-05-13
- Applicants: Medimmune, LLC
- Inventors: MANUEL BACA; STACEY DRABIC; PETER EMTAGE; RONALD HERBST
- Web page: https://patentgrep.com/patent/US20210260159A1

## CPC

- A61K 38/179: {for growth factors; for growth regulators}
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/70575: {NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525)}
- C07K 2317/30: characterized by aspects of specificity or valency
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided herein is a CD40L-Fc fusion protein and methods of using the fusion protein in the treatment of cancer comprising administering the CD40L-Fc fusion protein or the CD40L-Fc fusion protein in combination with one or more immune checkpoint inhibitors (e.g., an anti-CTLA4 antibody, anti-PD-L1 antibody).

## Claims

### Claim at position 1

1-24. (canceled)

### Claim 25

A method of activating a CD40 polypeptide, comprising contacting the CD40 polypeptide with a single chain fusion selected from the group comprising amino acid SEQ ID: 9, SEQ ID NO: 10, and SEQ ID NO: 11 fusion protein.

### Claim 26 (depends on 25)

The method of claim 25, wherein the fusion protein or dimer binds up to six CD40 polypeptides.

### Claim 27 (depends on 26)

The method of claim 26, wherein the CD40 polypeptide is on a cell.

### Claim 28 (depends on 27)

The method of claim 27, wherein the cell is in a subject.

### Claim 29 (depends on 28)

The method of claim 28, wherein the cell expresses a CD40 polypeptide.

### Claim 30 (depends on 29)

The method of claim 29, wherein the cell is an antigen presenting cell, macrophage, B-cell, or dendritic cell.

### Claim 31

A method of enhancing an anti-tumor immune response in a subject comprising administering to the subject a single chain fusion selected from the group comprising amino acid SEQ ID: 9, SEQ ID NO: 10, and SEQ ID NO: 11.

### Claim 32 (depends on 31)

The method of claim 31, wherein the subject has cancer.

### Claim 33

A method of treating a subject having cancer comprising administering to the subject a single chain fusion selected from the group comprising amino acid SEQ ID: 9, SEQ ID NO: 10, and SEQ ID NO: 11 and one or more immune checkpoint inhibitors.

### Claim 34 (depends on 33)

The method of claim 33, wherein the one or more immune checkpoint inhibitors comprises a PD-L1 or CTLA-4 antagonist.

### Claim 35 (depends on 34)

The method of claim 34, wherein the PD-L1 or CTLA-4 antagonist is an antibody.

### Claim 36 (depends on 35)

The method of claim 35, wherein the anti-PD-L1 antibody is durvalumab and the anti-CTLA-4 antibody is tremelimumab.

### Claim 37 (depends on 35)

The method of claim 35, wherein the anti-PD-L1 antibody comprises a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 18; a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 19; a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 20; a light chain CDR1 having the amino acid sequence of SEQ ID NO: 21; a light chain CDR2 having the amino acid sequence of SEQ ID NO: 22; and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 23.

### Claim 38 (depends on 35)

The method of claim 35, wherein the anti-PD-L1 antibody comprises a light chain having the amino acid sequence of SEQ ID NO: 16 and a heavy chain having the amino acid sequence of SEQ ID NO: 17.

### Claim 39 (depends on 35)

The method of claim 35, wherein the anti-CTLA-4 antibody comprises a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 28; a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 29; a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 30; a light chain CDR1 having the amino acid sequence of SEQ ID NO: 31; a light chain CDR2 having the amino acid sequence of SEQ ID NO: 32; and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 33.

### Claim 40 (depends on 35)

The method of claim 35, wherein the anti-CTLA-4 antibody comprises a light chain having the amino acid sequence of SEQ ID NO: 26 and a heavy chain having the amino acid sequence of SEQ ID NO: 27.

### Claim at position 18

42-48. (canceled)
